Cyclerion Therapeutics, Inc. (CYCN) Stock Price, Analysis & Data
Intrinsic value
See plans →Analyst Forecast
Stock Forecasts →$8.00
65.99% downside
You're seeing the free overview
Create a free account to explore more research on this ticker.
Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $0 | n/a | -100.00% |
| EPS | -$1.33 | +$1.33 | n/a |
Metrics
- Bid
- 2.52
- Market Cap
- 15.7M
- Revenue (ttm)
- 1.9M
- Net Income (ttm)
- -6.71M
- 1.75
- -11.62
- n/a
- -17.95
- P/B (ttm)
- 2.81
- P/S (ttm)
- 8.28
- Earnings Date
- n/a
- Ask
- 4.09
- Volume
- 435,847
- Avg. Volume (20D)
- 7,892
- Open
- 3.72
- Previous Close
- 23.52
- Day's Range
- 2.82 - 23.52
- 52-Week Range
- 2.82 - 59.36
- Analyst
- n/a
- Price Target
- 8 (-65.99%)
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Cyclerion Therapeutics, Inc.
View profile →Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.